We evaluated the performance of the Kodak DTSC Module for determination of alanine aminotransferase (ALT; EC 2.6.1 .2), aspartate aminotransferase (2.5.1 .2), alkaline phosphatase (3.1.3.1), creatine kinase (2.7.3.2), gamma-glutamyltransferase (2.3.2.2) , and lactate dehydrogenase (1.1.1.27). The DTSC is a "special chemistry" accessory for the 0T60 analyzer; the same multilayer film technology as that of the Ektachem 700 is used. The overall precision, assessed over a three-month period with two serum-based quality control materials, ranged from 2.2 to 8.0%. DTSC results for patients' specimens correlated well with those by the Technicon RA-1000 analyzer. The performance of the analyzer in linearity and interference studies was satisfactory for clinical use. The DTSC is simple to operate and has no technique-dependent step; it should be useful for the physician's office laboratory.
Materials and Methods

Instrument and Reagents. In this evaluation,
we used a IYFSC Module (Eastman Kodak Co., Rochester, NY 14650) "interfaced" with a Kodak DT6O analyzer (1,2). The testing is controlled via the keyboard on the DT6O. The system uses colorimetric slides based on the same methodologies as those in the Ektachem 700 analyzer. However, each reagent slide for the DTSC contains a bar-code label, and is individually wrapped for single use. The bar-code reader in the DTSC automatically identifies the test to be performed when the bar code on the slide is read. To perform an analysis, the operator loads a reagent slide in the DTSC and dispenses 10 p.L of serum or plasma onto the slide with the DTSC pipet, a motorized, battery-powered pipet that is specially dosigned to aspirate and deposit a 10-pL drop of sample. The analyzer performs all subsequent operations necessary to arrive at a test result. All results are automatically printed by the printer in the DT6O. The user can also request via the DT6O keyboard the display of results of the last 15 tests on the DTSC. Calibration of the assays was performed twice in Department of Laboratory Medicine, The University Hospital, Boston University Medical Center, Boston, MA 02118.
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Precision.
The overall precision for each enzyme assay was assessed with the DT Control and Ektachem Control level I. These lyophilized, serum-based, quality-control materials were reconstituted daily, and assayed twice a day during three months.
Linearity. By assaying mixtures of patients' specimens containing high and low activities of the enzyme, we determined the dynamic ranges of linearity for each assay.
Linear-regression
analyses of the measured values vs the expected values were made.
Method comparison. Patients' results for serum samples as measured by the DISC were compared with those by the RA-1000 random-access analyzer (Technicon Instruments Corp., Tarrytown, NY 10591).
Interference study. We studied the effect ofhemoglobin (at final concentrations up to 5 g/L) on results for all assays except ALT and lactate dehydrogenase (LD). Hemolysates were prepared by centrifuging whole blood, washing the erythrocytes three times with isotonic saline, and lysing them with de-ionized water. This hemolysate was diluted with different quantities of do-ionized water, and the hemoglobin concentrations were measured with the TOA Sysmex E-5000 analyzer (TOA Med. Co., Kobe, Japan). The hemolysate preparations were added to a pooled serum for which the enzyme activities had been established. The enzyme activities in these mixtures were determined.
We evaluated the effect of bilirubin (at final concentrations up to 250 mgfL) on all six assays. Bilirubin (Sigma Chemical Co., St. Loins, MO) was dissolved in dimethyl sulfoxide as described (3) and used in the interference study.
To study the effect of lipemia, serum samples with known activities of the enzymes were supplemented with various amounts of "10% Intralipid"
(Kabi Vitrum Inc., Alameda, CA 94710) to yield triglyceride concentrations up to 10 g/L.
In addition, some patients' specimens with moderate to gross lipemia had the activity of each enzyme measured before and after ultracentrifugation.
Results
Precision and linearity.
For various concentrations of serum-based quality-control materials, the within-day CVs ranged from 1.4 to 5.1%; the total CVs for the three-month period ranged from 2.2 to 8.0% (Table 1) . We found the dynamic ranges of linearity for ALP, creatine kinase (CK), and LD to be not as wide as claimad by the manufacturer (Table 2) .
Comparison studies. In Table 3 we compare patients' results for serum samples measured with the DTSC and the RA-1000. The correlations were good for all six tests except for two specimens in the AST assay. The results for the two specimens were 252 and 361 UIL by the HA-bOO, and 383 and 556 U/L by the DTSC, respectively. The two corresponding data points were at 8.5-and 13.2-fold the S value above the regression line in the correlation graph (not shown). These specimens, each from a patientinthe intensive-care unit, had high AST results (six-to ninefold the upper limIt of reference interval) by both the DTSC method and the RA-1000 method.
Interference Studies
Hemoglobin. The threshold concentrations of hemoglobin that caused a change >10% in the test result or produced an error code (with no test result) were approximately 2500 mg/L for ALP, ALT, and CK, and approximately 1500 mg/L for glutamyltransferase (GGT). AST and LD were excluded from this study because their concentrations inside the erythrocyte much exceed those in the plasma.
Bilirubin. A high concentration of bilirubin (250 mgfL) changed the test result by >10% or produced an error code in ALT, AST, ALP, and GOT, but not in CK or LD. Moderate concentration of bilirubin (125 mg/L) caused <10% change in results for all six tests.
Lipemia. We found <10% changes in the measured activities of all six enzymes when serum poolswere supplemented with "Intralipid" to give final concentrations of triglycerides up to 10 gIL. Similar findings were obtained when specimens with moderate to gross lipemia were analyzed before and after ultracentriftigation.
Discussion
We found the overall precision of the DTSC satisfactory for clinical use. No significant difference in precision was noted when operators of different levels of skill were compared. For example, the within-day precision (CV, n = 10) of the AST test attained by a physician with no prior experience in laboratory testing was 2.5%, compared with 3.0% by an experienced research-and-development technologist in our laboratory. We believe that the motorized pipet plays a key role in minimizing potential imprecision from sample handling.
We found the ranges of linearity not as wide as the "analyzer ranges" claimed by the manufacturer. The discrepancies may be due to different criteria used in establishing the ranges. Nevertheless, the linear ranges that we found are satisfactory for clinical use and comparable to those of the RA-1000, a much bigger instrument.
The DTSC results for patients' specimens correlated well with those by the HA-bOO, except for the AST test on two specimens from patients in the intensive-care units. The discrepancy was due to the AST reagent we used with the RA-1000; it did not contain pyridoxal phosphate. The AST reagent of the DTSC contains a large amount of pyridoxal phosphate to rapidly activate AST. Significantly lower results have been reported in severely ill patients when the AST reagent was not supplemented with pyridoxal phosphate, presumably owing to a deficiency of this vitamin in those patients (4) . The discrepancy in our results disappeared completely when we added pyridoxal phosphate to the RA-1000 reagent.
Among the common interferences studied, lipemia did not interfere with the DTSC tests. When specimens with severe hemolysis or icterus were analyzed, significant effects were found in some of the tests. An interference with the U) assay was noted with one specimen from a patient undergoing chronic ambulatory hemodialysis for renal insufficiency. The DTSC result correlated poorly with that from the HA-1000: 332 U/L by BA-bOO and 437 U/L by DTSC; the data point was at 6.5-fold the S, value from the regression line. Large clot formation was noted when protamine sulfate was added to the specimen. The removal offibrin increased the DTSC result by 48% to 649 UIL, and decreased the RA-1000 result by 16% to 277 UIL; good correlation (i.e., the data point was within 1 S,.. from the regression line) was obtained after this treatment. In the Ektachem product literature, the manufacturer has warned users about the potential interference due to fibrin materials in the specimen.
We conclude that the DTSC is satisfactory in overall analytical performance. We studied intra-individual variation in total and high-density lipoprotein (HDL) cholesterol in healthy volunteers (22 men and 19 women, ages 19 to 62 years) on controlled natural diets. The within-person coefficient of variation (CV) depended on the interval between blood samples, increasing from about 2% to 3% for measurements made 24 h apart to 4% to 5% for measurementsmade at four-day intervals or longer.
We conclude that within-subject fluctuations in total and HOL cholesterol have a time constant of several days. Multiple measurements are generally needed to decide whether an asymptomatic subject exceeds a certain concentration of total or HDL cholesterol; we recommend that such measurements be made at least four days apart.
Additional Keyphrases: intra-individual variation diet-related effects heart disease
A high concentration of cholesterol in blood is among the most clearly established risk factors for coronary heart disease. To decrease the incidence of coronary heart disease, itis recommended that people with high-and moderate-risk concentrations of cholesterol be treated (1). However, the classification of people into high-, moderate-, and low-risk categories is complicated by the high ratio of within-to between-person variance. Within-person coefficients of variation (CVs) for subjects on their usual diets range between 1.5% and 8.0% for total cholesterol and between 4.0% and 9.4% for high-density lipoprotein (HDL) cholesterol (2, 3) . The extent of the variation is related to the nature of the subjects, the degree of dietary control, the laboratory precision, and the interval between consecutive measurements (2) (3) (4) . To decrease the within-person variance, serial samples should be drawn (5). However, if these samples are drawn within a relatively short interval, then the estimations may be interdependent, so that the precision gained Our findings may be helpful in planmng studies involving estimates of a subject's true mean concentrations of total and HDL cholesterol in serum.
Materials and Methods
Study Design
The data were obtained in a series of four controlled experiments on the effect of diet on serum lipids. Subjects received natural mixed diets in which 11-14% ofthe energy (calories) was provided by protein, 41-45% by fat, 39-45% by carbohydrates, and 1-3% from ethanol; 30 to 43 g of dietary fiber was ingested daily. The fatty acid composition and cholesterol content of the diets varied between experimental periods. Each diet period lasted from two to four weeks. When a diet was begun, the concentrations of lipids in the subjects' blood achieved a new steady state in about 11 days (6). Therefore, we used the results for blood lipids only after they had stabilized after the change in diet. These results were the "baseline" values for that diet. Details of the experimental design and particulars of the diets have been published (6, 7).
Subjects
The participants in the four experiments were healthy normolipemic volunteers from the general population, living in or near Wageningen, a coflege town of 30000 inhabitants in the central part of The Netherlands, 80 km from Amsterdam. Altogether, 22 men and 19 women, ages 19-62 years (mean 32 years), participated in two or more of the different studies. The mean body mass index was 22.3 kg/m2 (range, 17.7-29.4 kg/m2). Each individual's body weight remained within 2% of the initial body weight during these studies.
The design and execution of the experiments were thoroughly explained to the subjects and informed consent was obtained. Prior approval was obtained from the MedicalEthical Committee of the Department.
